title: [Diabetes].
abstract: In 2004, a new insulin analogue was launched, Detemir insulin (Levemir). Detemir insulin is a long acting insulin and has a lower within-subject variability in comparison with other insulins. The recently published results of the CARDS study (atorvastatin treatment) also emphasize the need for a more aggressive attitude toward cardiovascular risk in diabetics even if LDL-cholesterol values are not particularly elevated. We will end this short review discussing the future of the inhibitor of GLP-1 degradation which in addition to a modest hypoglycaemic effect seems to be able to prevent apoptosis of insulin producing beta cells.
authors.affiliation: info@diabetelugano.org
authors.forename: P
authors.initials: P
authors.lastname: Gerber
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000819:agonists / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting
chemical_list: D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir